Dietary corosolic acid ameliorates obesity and hepatic steatosis in KK-Ay mice.
Corosolic acid (CRA), a constituent of Banaba leaves, has been reported to exert anti-hypertension, anti-hyperinsulinemia, anti-hyperglycemia, and anti-hyperlipidemia effects as well as to induce anti-inflammatory and anti-oxidative activities. The aim of this study was to investigate the inhibitory effects of CRA on the development of obesity and hepatic steatosis in KK-Ay mice, a genetically obese mouse model. Six-week-old KK-Ay mice were fed a high fat diet for 9 weeks with or without 0.023% CRA. Nine-week CRA treatment resulted in 10% lower body weight and 15% lower total fat (visceral plus subcutaneous fat) mass than in control mice. CRA treatment reduced fasting plasma levels of glucose, insulin, and triglyceride by 23%, 41%, and 22%, respectively. The improved insulin sensitivity in CRA-treated mice may be due on part to the increased plasma adiponectin and white adipose tissue (WAT) AdipoR1 levels. In addition, CRA treatment increased the expression of peroxisome proliferator-activated receptor (PPAR) alpha in liver and PPAR gamma in WAT. This is the first study to show that CRA treatment can contribute to reduced body weight and amelioration of hepatic steatosis in mice fed a high fat diet, due in part to increased expression of PPAR alpha in liver and PPAR gamma in WAT.
Yamada
Kotaro
K
Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
Hosokawa
Masaya
M
Yamada
Chizumi
C
Watanabe
Rie
R
Fujimoto
Shimpei
S
Fujiwara
Hideya
H
Kunitomo
Masaru
M
Miura
Toshihiro
T
Kaneko
Tetsuo
T
Tsuda
Kinsuke
K
Seino
Yutaka
Y
Inagaki
Nobuya
N
D052242:Adiponectin / Q000096:biosynthesis; D000273:Adipose Tissue / Q000473:pathology; D052436:Adipose Tissue, White / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D019440:Anti-Obesity Agents; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000473:pathology; D004032:Diet; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism; D008099:Liver / Q000473:pathology; D008297:Male; D051379:Mice; D009765:Obesity / Q000188:drug therapy* / Q000473:pathology; D010084:Oxidation-Reduction; D047493:PPAR alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D054419:Receptors, Adiponectin / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014280:Triglycerides / Q000096:biosynthesis; D014315:Triterpenes / Q000494:pharmacology*
D052242:Adiponectin; D019440:Anti-Obesity Agents; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D005227:Fatty Acids; D047493:PPAR alpha; D054419:Receptors, Adiponectin; D014280:Triglycerides; D014315:Triterpenes; C475419:adiponectin receptor 1, mouse; C475421:adiponectin receptor 2, mouse; C113861:corosolic acid